Growth to fuel new life sciences facilities; Teva will appeal verdicts in propofol cases;

> The life sciences sector in North America is expected to see fourth-quarter growth, with about $2 billion being put toward new laboratories, manufacturing sites and facilities. Article

> Teva Pharmaceutical Industries ($TEVA) maintains--as it has in the first two related trials--that allegations against it in a third trial after a Nevada hepatitis-C outbreak resulting from reuse of single-use vials of propofol are "without merit" and it will appeal. Story

> Takeda Pharmaceutical President Yasuchika Hasegawa says that rather than targeting additional acquisitions, the company will focus on integrating its latest, Nycomed, in Switzerland. News

> CSL chief Brian McNamee is cautious about further development and manufacture of vaccines: "We might creep into vaccines for a narrow disease, but we are not into mass vaccinations." Report

> A new committee of the Massachusetts Biotechnology Council represents contract manufacturers and contract research organizations, a reflection of their expanded presence in the Bay State. Story (sub. req.)

> Given their poor condition, the newly relicensed Indian vaccine-making facilities BCG VL Chennai and Pasteur Institute of India, Coonoor, may be unproductive until 2012. Item

> PakSense has unveiled the XpressPDF temperature monitoring label, which tracks both time and temperature. Release

> Unlike the U.S., most countries sell generics as branded products at up to 80% of the original price. Piece

> The Beijing Centers for Disease Control and Prevention has named Sinovac Biotech one of the four manufacturers of seasonal flu vaccine. Story

Sponsored By Digital Pharma Europe

Fierce Pharma Marketing is excited to announce the first virtual Digital Pharma Europe!

This summit will profile best-in-class case studies and senior-level discussions from leaders who are innovating the way we look at the intersection of digital technologies and marketing in Europe.